[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-colon-or-rectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-colon-or-rectal-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,63,101,128,168,192,229,255,281,302,324],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":41,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100644985","clonal-hematopoiesis-chemotherapy-and-radiation-effects-study-100644985",false,"NCT07675967","Clonal Hematopoiesis Chemotherapy and Radiation Effects Study","CH CARE","Inclusion Criteria:\n\n* Participants to be included in this study include the following:\n* Adults age \\>18 years\n* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)\n* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).\n* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.\n\nExclusion Criteria:\n\n* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure\n* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)\n* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.\n\nThe study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).\n\nUltimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Lung Cancer (Diagnosis)","Osteochondroma","Spitz Nevus","Solid Cancers","Breast Cancer","Gastric (Stomach) Cancer","Colorectal (Colon or Rectal) Cancer","Sarcoma","Ovarian Adenocarcinoma","Uterine Adenocarcinoma","Endometrial Adenocarcinoma","Esophageal Adenocarcinoma","Head and Neck Cancer","Therapy-Related Acute Myeloid Leukemia","Therapy-Related MDS","Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Clonal Cytopenia of Undetermined Significance",[42,43,44,45,46,47,48,49],"Adult cancer survivors","Precursor Lesions","clonal hematopoiesis","chemotherapy","radiation","therapy-related myeloid neoplasms","CCUS","clonal hematopoiesis of indeterminate potential","RECRUITING","2026-06-29",{"date":53,"type":54},"2026-06-30","ACTUAL",{"date":56,"type":54},"2025-04-04",{"date":58,"type":20},"2035-03-31",{"name":60,"class":61},"Dana-Farber Cancer Institute","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":62},"100625196","utero-ovarian-transposition-in-patients-with-pelvic-malignancies-undergoing-whole-pelvic-radiotherapy-100625196","NCT07419490","Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy","A Phase I Assessment of Utero-ovarian Transposition (UOT) for Fertility Preservation in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy (WPXRT)","UOT WPXRT","Inclusion Criteria:\n\n1. Age: Women 18 - 40 years of age who wish to preserve their fertility.\n2. Malignancy: Diagnosis of pelvic malignancies that require radiotherapy, including:\n\n   1. Colon and rectal cancer with tumors.\n   2. Anal cancer.\n   3. Other pelvic malignancies that require administration of WPXRT.\n3. Desire for Fertility Preservation: The patient expresses a clear desire to preserve fertility and the ability to carry a pregnancy in the future.\n4. Preoperative Ovarian Function: The patient must have normal ovarian function, demonstrated by specific hormonal values, including:\n\n   1. Follicle-Stimulating Hormone (FSH): \\\u003C10 IU\u002FL\n   2. Luteinizing Hormone (LH): within normal reference range for reproductive age (typically 1.5-8 IU\u002FL in the early follicular phase).\n   3. Anti-Müllerian Hormone (AMH): \\>1 ng\u002FmL\n   4. Estradiol (E2): within the normal range for the follicular phase (usually 30-120 pg\u002FmL).\n5. No Distant Metastasis: Absence of metastatic disease confirmed by imaging (CT, MRI, or PET scans).\n6. Body Mass Index (BMI) \\\u003C 35.\n7. Signed Informed Consent.\n\nExclusion Criteria:\n\n1. Advanced Cancer Stage: Patients with locally advanced or metastatic disease.\n2. Significant Uterine Pathology: Presence of large uterine fibroids, adenomyosis, or other intrauterine pathologies that would complicate the procedure or future pregnancy.\n3. Poor General Health or Comorbidities: Severe medical conditions that contraindicate surgical intervention, that include but not limited to:\n\n   * Cardiovascular Disease:\n\n     1. Recent (within 6 months) myocardial infarction (MI).\n     2. Ejection fraction (EF): EF \\\u003C30%.\n     3. Uncontrolled hypertension: Systolic BP \\>180 mmHg or Diastolic BP \\>110 mmHg prior to surgery.\n     4. Severe aortic stenosis: Valve area \\\u003C1 cm² with symptomatic status.\n   * Uncontrolled Diabetes Mellitus:\n\n     1. Hemoglobin A1c (HbA1c) \\> 9%\n     2. Persistent fasting glucose \\>250 mg\u002FdL preoperatively despite optimization.\n   * Severe Respiratory Diseases:\n\n     1. Forced expiratory volume (FEV1): \\\u003C50%.\n     2. Oxygen saturation: Resting SpO₂ \\\u003C88% on room air without supplemental oxygen.\n     3. CO2 retention: PaCO₂ \\>50 mmHg.\n   * Connective Tissue Disorders:\n\n     1. Severe systemic lupus erythematosus (SLE): Active lupus nephritis with GFR \\\u003C30 mL\u002Fmin.\n     2. Scleroderma with severe pulmonary hypertension or FVC \\\u003C50% predicted.\n     3. Rheumatoid arthritis with severe cervical spine instability (atlantoaxial subluxation).\n   * Severe Inflammatory Bowel Disease (IBD):\n\n     1. Severe Crohn's or ulcerative colitis flares with C-reactive protein (CRP) \\>10 mg\u002FL and hypoalbuminemia (Albumin \\\u003C2.5 g\u002FdL).\n     2. Severe malnutrition: BMI \\\u003C18.5 kg\u002Fm² or Prealbumin \\\u003C10 mg\u002FdL\n   * Steroid dependency:\n\n     1. Chronic steroid use (\\>20 mg prednisone daily) with no feasible taper pre-surgery.\n4. Prior Pelvic Radiotherapy.\n5. Prior history of systemic chemotherapy and immunotherapy that resulted in significant toxicity and residual deficit.\n6. Pregnancy: Patients who are currently pregnant are excluded from consideration for uterine transposition.\n7. Unsuitable for Ovarian Function Preservation: Women with signs of poor ovarian reserve, including:\n\n   * FSH: \\>10 IU\u002FL\n   * AMH: \\\u003C1 ng\u002FmL\n   * Estradiol: outside normal range.\n8. Non-Candidate for Fertility: Patients with contraindications to future pregnancy, such as severe uterine abnormalities or significant risk for pregnancy-related complications.\n9. Body Mass Index (BMI) ≥35.\n10. Absence of One of the Gonadal Vessels.\n11. Other unlisted conditions or diagnoses that, in the opinion of the primary investigator, render the patient an unsuitable candidate for uteroovarian transposition.","FEMALE","18 Months","40 Months",{"count":75,"type":20},26,"INTERVENTIONAL",[78],"NA","This study is designed as a Phase I clinical trial enrolling female patients aged 18-40 years who have been diagnosed with pelvic malignancies requiring whole pelvic external radiation therapy (WPXRT) and who express interest in preserving fertility and ovarian function.\n\nThe trial's primary objective is to assess the feasibility and safety of uterine and ovarian transposition (UOT). Premenopausal women under the age of 40 will undergo UOT using a novel minimally invasive approach.\n\nFeasibility and safety will be evaluated through standardized postoperative assessments, including:\n\n(A) success in mobilizing and repositioning the uterus, ovaries, and fallopian tubes while maintaining vascular integrity; (B) documentation of surgical complications; (C) monitoring the timeliness and adherence to planned WPXRT.\n\nTo enhance safety and optimize outcomes, intraoperative imaging with indocyanine green fluorescence and Doppler ultrasonography will be employed.\n\nShort-term success will be defined by technical success in repositioning the uterus and ovaries with preserved vascular integrity, absence of major surgical complications, and timely initiation and completion of WPXRT.\n\nLong-term success will be evaluated by the preservation of fertility.\n\nThe study's primary objective is also to evaluate surgical, reproductive, and quality-of-life outcomes following UOT. This objective will determine the procedure's efficacy in preserving ovarian and menstrual function and its potential to support future pregnancies.\n\nEndpoints include:\n\n(A) maintenance of normal premenopausal levels of FSH, LH, AMH, and estradiol at defined postoperative intervals; (B) assessment of menstrual timing, regularity, and characteristics to document return of ovulatory cycles; (C) evaluation of uterine integrity and reproductive potential using pelvic ultrasonography; (D) comprehensive evaluation of patient quality of life encompassing physical, emotional, sexual, and reproductive well-being.\n\nThese measures will inform optimization of surgical techniques and provide a foundation for scaling the procedure to a broader population in future studies.",[30,81,82],"Pelvic Malignancies","Oncofertility",[84,85,86,87,88,89,90,91],"uterine transposition","utero-ovarian transposition","oncofertility","pelvic radiation","pelvic malignancies","rectal cancer","colorectal malignancies","fertility preservation","2026-06-23",{"date":94,"type":54},"2026-06-24",{"date":96,"type":54},"2026-04-01",{"date":98,"type":20},"2031-06",{"name":100,"class":61},"University of South Florida",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":109,"targetDuration":111,"studyType":21,"phases":4,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":62},"100641271","non-operative-management-and-following-immunotherapy-for-colorectal-cancer-and-other-gi-cancers-100641271","NCT07656740","Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers","Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers (NOMIC Trial)","NOMIC","Inclusion Criteria:\n\n1. Retrospective Cohort Inclusion Criteria\n\n   * Pathologically confirmed gastrointestinal malignancy determined as MSI-H\u002FdMMR or POLE mutation, and initially resectable.\n   * Completed prior immunotherapy.\n   * No evidence of distant metastasis.\n   * Managed with W\\&W, LE, endoscopic surgery, or radical operation after treatment.\n2. Prospective Cohort Inclusion Criteria\n\n   * Pathologically confirmed gastrointestinal malignancy determined as MSI-H\u002FdMMR or POLE mutation, and initially resectable.\n   * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n   * Immunotherapy status: naive, currently receiving, or completed treatment, and evaluated by the PKUCH-NOMIC research group as cCR\u002Fnear-cCR or Non-cCR (≤ ymrT2N0).\n   * No evidence of distant metastasis.\n   * Absence of emergencies requiring immediate surgery (e.g., hemorrhage, perforation, obstruction).\n\nExclusion Criteria:\n\n* Recurrent gastrointestinal tumors.Initial presence of unresectable distant metastases.\n* Serum creatinine \\> 1.5 times upper limit of normal (ULN).\n* History of pelvic radiation therapy.Inability to tolerate MRI examinations.\n* History of other malignancies within the past 5 years with a survival rate significantly lower than the historical rectal cancer survival data of this center (except adequately treated basal cell carcinoma, cutaneous squamous cell carcinoma, small renal cell carcinoma, breast cancer, and papillary thyroid carcinoma).\n* Arterial thromboembolic events within the past 6 months (e.g., angina, myocardial infarction, transient ischemic attack \\[TIA\\], cerebral vascular accident \\[CVA\\]).\n* Prior receipt of other types of investigational anti-tumor therapies.\n* Pregnant or lactating women.\n* Concomitant diseases or mental health conditions that may interfere with study participation.",{"count":110,"type":20},50,"3 Years","This is a single-center, bidirectional (retrospective and prospective) registry study aimed at evaluating the safety and efficacy of Non-Operative Management (NOM) and Organ-Preserving Functional Surgery (OPFS) in patients with mismatch repair-deficient\u002Fmicrosatellite instability-high (dMMR\u002FMSI-H) or POLE-mutated gastrointestinal (GI) cancers who received neoadjuvant immunotherapy.Patients achieving a clinical complete response (cCR) or near-cCR may undergo a \"Watch \\& Wait\" (W\\&W) strategy, while those with near-cCR or non-cCR ($\\\\le ymrT2N0$) may undergo local excision (LE) or endoscopic resection (ESD\u002FEMR). Patients undergoing radical operation (RO) will serve as the control cohort to compare oncological outcomes and safety data.",[114,30,115],"Gastrointestinal Cancer","Stomach (Gastric) Cancer",[117,118],"dMMR\u002FMSI-H","POLE-mutated","NOT_YET_RECRUITING","2026-06-15",{"date":122,"type":54},"2026-06-18",{"date":120,"type":20},{"date":125,"type":20},"2030-10-15",{"name":127,"class":61},"Peking University Cancer Hospital & Institute",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":76,"phases":137,"briefSummary":139,"conditions":140,"keywords":147,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":167},"100617629","phase-1-a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mssmsi-l-colorectal-cancer-100617629","NCT07321106","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS\u002FMSI-L Colorectal Cancer","A Phase 1, First-in-human (FIH), Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic Microsatellite Stable (MSS)\u002FMicrosatellite Instability Low (MSI-L) Colorectal Cancer","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Participant with MSS\u002FMSI-L CRC, who has exhausted at least one prior line of standard systemic therapy for their current malignancy.\n* Participant with genomic aberrations, including but not limited to BRAFV600E mutations and HER2 amplifications, for which FDA-approved targeted therapies are available, must:\n\n  * Have received prior treatment with applicable FDA-approved targeted therapies AND\n  * Either have experienced disease progression, be refractory, or be intolerant to directed molecular therapy.\n* Participant able to provide archival tissue sample or fresh biopsy tissue sample\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Participant whose CRC tumor tissues have been identified as dMMR or MSI-H\n* Known history of solid organ or tissue transplant; history of interstitial lung disease or non-infectious pneumonitis.\n* Untreated central nervous system (CNS) metastatic disease.\n* Active autoimmune disease that has required systemic treatment within the past 2 years (participants with hormone replacement therapy for adequately controlled endocrinopathy are allowed in the study).\n* History of recent infection (within 4 weeks of C1D1) considered to be caused by one of the pathogens: HSV1, HSV2, VZV, EBV, CMV, measles, Influenza A, Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni, or enterovirus D68.\n* Known seropositive for human immunodeficiency virus, hepatitis B surface antigen, or antibody to hepatitis C virus with confirmatory testing and requiring anti-viral therapy.\n* History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.\n* Significant medical comorbidities, including uncontrolled hypertension (diastolic blood pressure \\>115 mm Hg), unstable angina, congestive heart failure (greater than New York Heart Association class II), severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, poorly controlled diabetes, severe chronic pulmonary disease, coronary angioplasty, or myocardial infarction within 6 months prior to screening, or uncontrolled atrial or ventricular cardiac arrhythmias.\n* Congenital long QT syndrome or a corrected QT interval (QTc) ≥480 ms at screening (unless secondary to pacemaker or bundle branch block).\n* Active second primary malignancy within 3 years of Screening other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, or ductal or lobular carcinoma in situ of the breast",{"count":136,"type":20},80,[138],"PHASE1","This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)\u002FMicrosatellite Instability Low (MSI-L) Colorectal Cancer",[141,142,30,143,144,145,146],"Colorectal Cancer","Colorectal Cancer (CRC)","CRC","Metastatic Colon Cancer","Colon Cancer","Advanced Colorectal Cancer",[148,149,150,151,152,153,154,155,156],"Oncology","Solid Tumor","Phase 1","First-in-Human","Dose Escalation","Open-Label","T-Cell Engager","TCE","CartographyBio","2026-06-09",{"date":159,"type":54},"2026-06-10",{"date":161,"type":54},"2026-01-15",{"date":163,"type":20},"2029-10",{"name":165,"class":166},"Cartography Biosciences","INDUSTRY",8,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":76,"phases":177,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":191},"100628477","phase-2-a-phase--clinical-trial-of-rc148-plus-chemotherapy-as-1l-therapy-for-unresectable-or-metastatic-colorectal-cancer-100628477","NCT07462143","A Phase Ⅱ\u002FⅢ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer","A Randomized, Multicenter, Phase Ⅱ\u002FⅢ Study of RC148 Combined With Chemotherapy Versus Bevacizumab Combined With Chemotherapy as First-line Treatment for Unresectable or Metastatic Colorectal Cancer","Inclusion Criteria:\n\n1. Voluntarily agree to participate in the study, sign the informed consent form, and be able to comply with the study protocol.\n2. Aged 18-75 years old (including 18 years old and 75 years old).\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n4. Expected survival period ≥ 12 weeks.\n5. At least one measurable lesion according to RECIST v1.1 criteria.\n6. Histologically or cytologically confirmed colorectal adenocarcinoma, judged by the investigator as unsuitable for curative treatment, and no prior systemic anti-tumor treatment in the recurrent or metastatic stage.\n7. Subjects must be able to provide tumor tissue samples for biomarker detection.\n8. Adequate bone marrow, liver, kidney, and coagulation function.\n9. Female subjects of childbearing potential must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment, and must have a negative blood pregnancy test within 7 days before study enrollment; male subjects must agree to use at least one medically approved contraceptive method during the study treatment and for 6 months after the end of the study treatment.\n\nExclusion Criteria:\n\n1. Known to have microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR).\n2. Imaging shows obvious tumor necrosis or cavitation, and the investigator judges that participation in the study may increase the risk of bleeding.\n3. Subjects with brain metastases.\n4. Toxicities from prior anti-tumor therapy have not recovered to ≤ grade 1 according to NCI-CTCAE v6.0.\n5. Known hypersensitivity or delayed-type allergy to any component of the study drug or similar drugs.\n6. Subjects with refractory nausea and vomiting, chronic gastrointestinal diseases, or other diseases that may interfere the adequate absorption, distribution, metabolism, or excretion of oral drugs.\n7. Subjects with acute, chronic, or symptomatic infections.\n8. Subjects with diagnosed or suspected interstitial lung disease (ILD), drug-related pneumonia, radiation pneumonitis, severe impairment of lung function, or other lung diseases.\n9. Subjects with active inflammatory bowel disease, a history of gastrointestinal perforation and\u002For fistula, or clinical symptoms of gastrointestinal obstruction.\n10. Subjects with severe arterial\u002Fvenous thromboembolic events within 6 months before randomization.\n11. Active gastrointestinal bleeding, hemoptysis, peptic ulcer, or hemorrhagic events requiring intervention within 28 days before randomization; or presence of severe esophagogastric varices or epistaxis.\n12. Presence of symptomatic or intervention-requiring third-space effusions.\n13. Subjects with active or previously diagnosed autoimmune diseases that may recur.\n14. History of other invasive malignant tumors within 5 years before randomization, or presence of any residual evidence of previously diagnosed malignant tumors.\n15. Subjects who are pregnant, lactating, or planning to become pregnant.","75 Years",{"count":136,"type":20},[178,179],"PHASE2","PHASE3","This is a Phase Ⅱ\u002FⅢ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)",[30],"2026-05-18",{"date":184,"type":54},"2026-05-22",{"date":186,"type":54},"2026-05-12",{"date":188,"type":20},"2030-12-31",{"name":190,"class":166},"RemeGen Co., Ltd.",19,{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":76,"phases":201,"briefSummary":202,"conditions":203,"keywords":216,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100633678","phase-1-phase-12-study-of-bhb810-in-advanced-gastric-and-gej-adenocarcinoma-100633678","NCT07529808","Phase 1\u002F2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma","Phase 1\u002F2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.\n* Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.\n\n  * Participants in Phase 1 Backfill Cohorts \\& Phase 2 must be CDH17-positive by central testing.\n  * Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.\n* At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)\n* Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.\n* Adequate organ and marrow function as defined in the protocol\n\nExclusion Criteria:\n\n* Prior cancer treatment as follows, relative to the first planned dose of trial intervention:\n\n  * Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)\n  * Monoclonal antibody-based therapy (including ADCs) within 4 weeks\n  * Immune checkpoint inhibitors within 4 weeks\n  * Wide-field radiation therapy (\\>30% marrow-bearing bones) within 4 weeks or \\\u003C 2 weeks of focal palliative radiation to nontarget lesions\n* Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)\n* Known hypersensitivity or allergic reaction to BHB810 or it's excipients\n* Left ventricular ejection fraction \\\u003C50% or history of congestive heart failure Class III\u002FIV\n* QTc interval \\> 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT\u002FQTc\n* Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant\n* Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.\n* Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention\n* Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.",{"count":200,"type":20},164,[138,178],"This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.",[204,205,29,206,207,208,209,210,211,212,30,213,214,215],"Gastric Cancer","Gastric Adenocarcinoma","Gastroesophageal Adenocarcinoma","Gastroesophageal Cancer (GC)","Gastroesophageal Junction (GEJ) Adenocarcinoma","Gastroesophageal Junction (GEJ) Cancer","Gastrointestinal Cancer Metastatic","Gastrointestinal Adenocarcinoma","Gastrointestinal Cancers","Pancreatic Cancer","CDH17-positive Advanced Solid Tumors","Advanced Gastric Cancer",[217,218,219],"Antibody Drug Conjugate (ADC)","Monomethyl Auristatin E (MMAE)","CDH17 protein","2026-05-05",{"date":222,"type":54},"2026-05-08",{"date":224,"type":20},"2026-06",{"date":226,"type":20},"2028-12",{"name":228,"class":166},"BigHat Biosciences, Inc.",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":238,"conditions":239,"keywords":240,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":62},"100609182","collagenase-biobank-study-100609182","NCT07211230","Collagenase Biobank Study","Collagenase Producing Bacteria as a Biomarker and Driver of Diet-induce Colorectal Cancer Recurrence and Metastasis Following Surgery","Inclusion Criteria:\n\n* English speaking.\n* All genders, races, and ethnicities.\n* Aged greater or equal to 18 years of age.\n* Ability to understand and the willingness to sign a written informed consent form.\n* Diagnosed with a colon adenocarcinoma or presumed adenocarcinoma in which surgical resection is recommended.\n* Have a planned surgical resection of the colon adenocarcinoma at the University of Chicago Comprehensive Cancer Center.\n* Reside within 150 miles of the University of Chicago Comprehensive Cancer Center.\n\nExclusion Criteria:\n\n* Stage IV colon adenocarcinoma (known metastatic disease).\n* Intravenous or oral antibiotic exposure within 30 days of surgery to treat an infection.\n* Prebiotic exposure within 30 days of surgery.\n* History of neoadjuvant chemotherapy\u002Fradiation to treat the primary colon adenocarcinoma.\n* History of chemotherapy\u002Fradiation to treat a separate malignancy within the last 6 months.\n* History or current ileostomy or colostomy.\n* Allergy to perioperative medications (oral neomycin\u002Fmetronidazole for preoperative bowel preparation, intraoperative prophylactic intravenous cefoxitin).\n* Patients who are pregnant.\n* Patients with a history of inflammatory bowel disease.\n* Patients with a history of bariatric surgery.\n* History of eating disorders.",{"count":237,"type":20},107,"The purpose of this study is to look at how bacteria present within the stool at the time of surgery and postoperatively may contribute to the development of cancer recurrence after surgery. By collecting stool and blood before and after surgery, the researchers hope to determine if certain types of bacteria, or products that the bacteria produce, promote the development of tumors after surgery. By collecting tumor tissue and growing cell lines, we hope this will help researchers better understand the behavior of these types of tumors.",[30],[241,242,243,244,245],"colorectal cancers","biobank","Collagenase Biobank","Tissue collection","stool collection","2026-04-07",{"date":248,"type":54},"2026-04-09",{"date":250,"type":20},"2026-08",{"date":252,"type":20},"2026-10",{"name":254,"class":61},"University of Chicago",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":265,"conditions":266,"keywords":269,"overallStatus":119,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":279,"locationsCount":62},"100629388","integrating-peritoneal-histological-growth-patterns-into-preoperative-decision-making-for-colorectal-peritoneal-metastses-100629388","NCT07474025","Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses","Integrating Peritoneal Histological Growth Patterns Into Preoperative Decision-Making for Colorectal Peritoneal Metastses: A Prospective Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed colorectal adenocarcinoma\n* Suspected or confirmed peritoneal metastases from colorectal cancer based on imaging or prior clinical evaluation\n* Patients undergoing staging laparoscopy and\u002For cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC) as part of standard clinical care\n* Availability of peritoneal metastasis tissue samples suitable for histopathological analysis\n* Written informed consent provided for participation in the study\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Peritoneal metastases originating from non-colorectal primary tumors\n* Absence of available or adequate peritoneal metastasis tissue samples for histological growth pattern analysis\n* Patients who decline or withdraw informed consent\n* Patients unable to provide informed consent","100 Years",{"count":264,"type":20},30,"Colorectal cancer (CRC) remains the third most commonly diagnosed malignancy worldwide and the second leading cause of cancer-related death, with approximately 15% of patients presenting with synchronous liver metastases (LM) and 7% with peritoneal metastases (PM) at diagnosis. Despite curative-intent resection of the primary tumor, 16-20% of patients subsequently develop metachronous LM and up to 19% develop PM within three years \\[1-5\\].\n\nSurgery remains the only potentially curative treatment for patients with colorectal peritoneal metastases (CRPM), offering long-term (\\>10years) disease-free survival (DFS) in a subset of highly selected patients \\[6,7\\]. However, selecting candidates for cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC) remains challenging and requires balancing the potential oncologic benefit of complete cytoreduction against perioperative risks and postoperative morbidity \\[6-8\\].\n\nConsequently, strong prognostic markers-clinical, biological, or genetic-are crucial to refine surgical decision-making. Currently, the two most consistent clinical determinants of outcome are the extent of disease (Peritoneal Cancer Index, PCI) and the completeness of cytoreduction (CC-score) \\[6-8\\]. Over the last decade, surgical selection has become more restrictive (e.g., PCI threshold moving from 25 to 17), and molecular profiles such as BRAF mutations have been associated with poor outcomes, potentially guiding against aggressive surgery in selected cases \\[8,9\\]. Yet, these markers are insufficient to fully capture inter-patient heterogeneity and do not reliably individualize surgical benefit \\[8,9\\].\n\nIn colorectal liver metastases (CRLM), the histological growth pattern (HGP) at the tumor-liver interface has emerged as a robust prognostic biomarker, with the desmoplastic HGP (d-HGP) associated with superior survival compared with replacement or pushing patterns \\[10,11\\]. International consensus guidelines have standardized HGP scoring for CRLM, enabling reproducible assessment and cross-study comparison \\[12\\]. Large multicentric cohorts also suggest possible modulation of HGP by systemic chemotherapy, supporting its value as a marker of intrinsic tumor biology and treatment response \\[13,14\\].\n\nTransposing this concept to the peritoneum, our group identified two reproducible peritoneal HGP in colorectal peritoneal metastases: the pushing pattern (P-HGP) and the infiltrating pattern (I-HGP). Across two monocentric studies, a dominant P-HGP (\\>50-60% of the tumor-peritoneum interface) was strongly associated with prolonged disease-free and overall survival (OS) \\[15,16\\].\n\nTaken together, these findings support HGP of PM as a potential histological biomarker to refine patient selection for CRS ± HIPEC beyond current clinical and molecular criteria.\n\nHowever, existing data derive exclusively from retrospective single-center cohorts, underscoring the need for prospective validation to:\n\nConfirm the independent prognostic value of HGP of PM (for overall and disease-free survival) in contemporary clinical practice; Standardize sampling and pathological assessment (standard operating procedures, central review, and interobserver reproducibility studies); Develop and validate a histo-prognostic scoring system integrating PM HGP with relevant clinicopathological variables, aimed at predicting patient outcomes and supporting preoperative decision-making for CRS ± HIPEC candidacy.\n\nThis prospective cohort study is designed to address these objectives without modifying standard care. By collecting clinicopathological and survival data prospectively, it will provide robust evidence for the integration of HGP into a multivariable prognostic model capable of stratifying surgical candidates and guiding individualized treatment strategies.",[267,141,30,268],"Peritoneal (Metastatic) Cancer","Histopathological Growth Patterns (HGPs)",[270,271,272],"Peritoneal cancer","Colorectal cancer","Histopathological Growth Patterns","2026-03-11",{"date":275,"type":54},"2026-03-16",{"date":277,"type":20},"2026-03",{"date":226,"type":20},{"name":280,"class":61},"Jules Bordet Institute",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":76,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":62},"100620706","phase-1-evaluation-of-circulating-immune-response-after-histosonics-in-colorectal-cancer-echo-crc-100620706","NCT07361107","Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)","ECHO CRC","Inclusion Criteria:\n\n* Gender: Both male and female patients will be eligible for enrollment.\n\n  * Age at least 18 years.\n  * Histologic (biopsy-proven) confirmation of metastatic microsatellite stable colorectal cancer with at least one radiographically evident hepatic metastasis.\n  * Planned treatment with standard-of-care histotripsy.\n  * Radiographic confirmation of hepatic metastases with computed tomography (CT) or magnetic resonance imaging (MRI), with CT preferred. Imaging must be performed within 60 days of the date of consent.\n  * Adequate organ and marrow function as defined below:\n\n    1. Absolute neutrophil count: ≥ 1,000\u002FmcL\n    2. Platelets: ≥ 100,000\u002FmcL\n    3. Total bilirubin ≤ 3x the upper limit of normal (ULN). This may be up to 5x ULN if Gilbert's syndrome is documented.\n    4. AST and ALT ≤ 8x institutional ULN.\n    5. Serum creatinine ≤ 2x ULN unless on dialysis.\n  * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3.\n  * Estimated life expectancy of at least 90 days as determined by the treating physician.\n  * Demographic group: There are no restrictions based on race or ethnicity. Efforts will be made to ensure a representative patient population reflecting the diversity of individuals affected by CRCLM.\n  * Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Major surgical procedure or significant traumatic injury within 14 days prior to histotripsy.\n\n  * Therapy with an investigational drug within 14 days prior to histotripsy.\n  * Clinically significant cardiovascular or cerebrovascular disease, including:\n\n    * Myocardial infarction within 3 months prior to enrollment.\n    * Unstable angina.\n    * Congestive heart failure (New York Heart Association Classification Class \\> II).\n\n      v. 3.0 22July2025 9\n    * Serious cardiac arrhythmia (controlled atrial fibrillation or definitively treated arrhythmias via ablation are not considered exclusion criteria).\n    * Cerebrovascular stroke with deficit within 3 months prior to enrollment.\n  * Active infection requiring systemic therapy within 14 days prior to histotripsy, unless deemed to be a chronic disease state by the study PI.\n  * Active pregnancy.\n  * Patients with active infections, autoimmune diseases requiring systemic immunosuppression, or other uncontrolled comorbidities that could interfere with study participation will be excluded.\n  * Severe cancer-associated cachexia that may interfere with systemic immune response, as assessed by the treating physician.\n  * Any ongoing medical illness or injury that would significantly impact tolerability of therapy, including but not limited to:\n\n    * Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture.\n    * Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding.\n    * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates histotripsy, may affect the interpretation of study results, or may render the patient at high risk for treatment complications.\n  * Anyone that is unable to consent due to cognitive, psychological or other reasons that impact their capacity.\n  * Deemed to be inappropriate for enrollment by the study PI.",{"count":289,"type":20},12,[138],"This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, including both primary and metastatic lesions. In this study, investigators aim to evaluate the kinetics of peripheral T-cell response following histotripsy of colorectal cancer liver metastases (CRCLM). Given the well-documented immune-tolerant tumor microenvironment of liver metastases and their role in systemic resistance to checkpoint inhibitors, investigators hypothesize that histotripsy-induced tumor disruption will lead to measurable alterations in peripheral T-cell clonal expansion and exhaustion markers. Investigators will assess these changes via serial blood draws before and after histotripsy, with the goal of characterizing the systemic immune impact of local tumor ablation. Findings from this study may inform future combination strategies integrating histotripsy with immunotherapy to enhance treatment response in microsatellite-stable CRC",[30],"2026-01-14",{"date":295,"type":54},"2026-01-22",{"date":297,"type":54},"2025-09-26",{"date":299,"type":20},"2027-09-27",{"name":301,"class":61},"Northwell Health",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":262,"enrollmentInfo":310,"targetDuration":4,"studyType":76,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":62},"100443180","colorectal-cancer-screnning-colonoscopy-under-hypnosis-100443180","NCT05051046","Colorectal Cancer Screnning Colonoscopy Under Hypnosis","Colorectal Cancer Screnning Colonoscopy Under Hypnosis: A Multicenter Randomized Non-Inferiority Trial","CODEPICCH","Inclusion Criteria:\n\n* Patients 18 years of age or older\n* Undergoing a screening colonoscopy (mass screening Fecal Immunochemical Test positive or as an individual (family history of colon cancer or adenoma, personal history of adenoma, cancer, chronic inflammatory bowel disease) or in the context of a transit disorder, hemorrhage or anemia\n* Affiliated with a French social security system\n* Having signed a written consent\n\nExclusion Criteria:\n\n* Patient requiring emergency colonoscopy\n* History of colonic resection\n* Carriers of behavioral disorders and\u002For psychiatric illness\n* Limited cognitive abilities making it impossible to read or fill out a discrete choice questionnaire (language problems, comprehension problems)\n* Contraindication to hypnosis, preventing quality interaction (comprehension and\u002For language problems, hearing impairment)\n* Contraindication to general anesthesia\n* Under a legal protection regime\n* Pregnant or breastfeeding woman",{"count":311,"type":20},600,[78],"Through this study, the effectiveness of hypnosis in the realization of a colonoscopy for the detection of colorectal cancer will be evaluated",[30],"2025-11-18",{"date":317,"type":54},"2025-11-24",{"date":319,"type":54},"2022-01-31",{"date":321,"type":20},"2028-02-07",{"name":323,"class":61},"University Hospital, Tours",{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":76,"phases":333,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":62},"100537025","comparison-of-intravenous-lidocaine-vs-ketamine-in-colorectal-surgery-100537025","NCT06272461","Comparison of Intravenous Lidocaine vs Ketamine in Colorectal Surgery","The Effect of Intravenous Lidocaine or Ketamine on Interleukin-6 Levels in Patients Undergoing Colorectal Surgery for Cancer: A Randomized Controlled Trial","INCLUSION CRITERIA:\n\n* Patients aged 18 or older.\n* American society of anesthesiologists' (ASA) physical status of I-III.\n* Elective open colorectal surgery.\n\nNON INCLUSION CRITERIA:\n\n* Patients with contraindications to lidocaine or ketamine.\n* Corticosteroid therapy within the last 6 months.\n* History of immunosuppressive therapy.\n* History of surgery in the last 3 months.\n* Personal medical history of inflammatory bowel disease.\n* Personal medical history of cardiac arrythmias or conduction disorders.\n* Alcohol or drug abuse.\n* Chronic use of opioids or benzodiazepines.\n\nEXCLUSION CRITERIA:\n\n* Severe intraoperative complications.\n* Duration of surgery longer than 5 hours.","90 Years",{"count":110,"type":20},[78],"Patients undergoing open colorectal surgery were randomly divided into two groups: Intravenous Lidocaine (IV-Lido) vs Intravenous Ketamine (IV-Keta).\n\nFor the IV-Lido group, patients received a loading dose of Lidocaine than a continuous infusion over twenty-four hours.\n\nFor the IV-Keta goup, patients received a loading dose of Ketamine than a continuous injection of Ketamine over twenty-four hours.\n\nPlasma concentrations of Interleukin-6(IL-6) were measured preoperatively before anesthetic induction and at twenty-four hour post operatively.",[30,336],"Inflammation","2025-11-15",{"date":315,"type":54},{"date":340,"type":54},"2023-10-01",{"date":342,"type":20},"2026-03-30",{"name":344,"class":61},"University Tunis El Manar"]